tetano
Editor, Senior Moderator
Expert Rev Vaccines. 2016 Sep 22. [Epub ahead of print]
[h=1]M2-based influenza vaccines: recent advances and clinical potential.[/h] Kolpe A[SUP]1,[/SUP][SUP]2[/SUP], Schepens B[SUP]1,[/SUP][SUP]2[/SUP], Fiers W[SUP]1,[/SUP][SUP]2[/SUP], Saelens X[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]INTRODUCTION:[/h] Current influenza vaccines can prevent disease caused by influenza viruses but require annual administration and almost yearly reformulation. An attractive alternative approach would be to use a vaccine that provides broad and, ideally, lifelong protection against all influenza A and B virus strains. The extracellular domain of matrix protein 2 (M2e) of influenza A viruses is conserved and thus fits well in such a broadly protective vaccine.
[h=4]AREAS COVERED:[/h] Recent advances in M2e vaccine design, the mode of action of M2e-based immunity and clinical progress of M2-based influenza vaccines. Expert Commentary: Many M2e vaccine have been successfully tested for efficacy against a panel of divergent influenza viruses in animal models. More recently, clinical studies have been conducted with M2e vaccine candidates, which demonstrated their safety and immunogenicity in humans. Efficacy studies in humans are still needed to provide evidence that an M2e-based vaccine can protect against human influenza.
[h=4]KEYWORDS:[/h] M2e; broadly protecting antibodies; broadly protective vaccines; clinical trial; influenza A virus; matrix protein 2
PMID: 27653543 DOI: 10.1080/14760584.2017.1240041
[PubMed - as supplied by publisher]
[h=1]M2-based influenza vaccines: recent advances and clinical potential.[/h] Kolpe A[SUP]1,[/SUP][SUP]2[/SUP], Schepens B[SUP]1,[/SUP][SUP]2[/SUP], Fiers W[SUP]1,[/SUP][SUP]2[/SUP], Saelens X[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]INTRODUCTION:[/h] Current influenza vaccines can prevent disease caused by influenza viruses but require annual administration and almost yearly reformulation. An attractive alternative approach would be to use a vaccine that provides broad and, ideally, lifelong protection against all influenza A and B virus strains. The extracellular domain of matrix protein 2 (M2e) of influenza A viruses is conserved and thus fits well in such a broadly protective vaccine.
[h=4]AREAS COVERED:[/h] Recent advances in M2e vaccine design, the mode of action of M2e-based immunity and clinical progress of M2-based influenza vaccines. Expert Commentary: Many M2e vaccine have been successfully tested for efficacy against a panel of divergent influenza viruses in animal models. More recently, clinical studies have been conducted with M2e vaccine candidates, which demonstrated their safety and immunogenicity in humans. Efficacy studies in humans are still needed to provide evidence that an M2e-based vaccine can protect against human influenza.
[h=4]KEYWORDS:[/h] M2e; broadly protecting antibodies; broadly protective vaccines; clinical trial; influenza A virus; matrix protein 2
PMID: 27653543 DOI: 10.1080/14760584.2017.1240041
[PubMed - as supplied by publisher]